Close Menu

NEW YORK (GenomeWeb) – Epigenomics of Germany said today that it has terminated its collaboration with China's BioChain for the licensing of the Septin9 marker and exclusive Chinese distribution rights for Epi proColon, Epigenomics' blood test for colorectal cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.